Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. develops engineered cells as medicines for patients, with programs that apply cell engineering, hypoimmune platform technology, and fusogen-based delivery. News about SANA commonly covers its type 1 diabetes cell-replacement work, including UP421 and SC451, and its in vivo CAR T program SG293 for CD19-directed therapy in B-cell cancers and B-cell-mediated autoimmune diseases.
Company updates also include preclinical and clinical data presentations, research collaborations, manufacturing and regulatory preparation, financial results, equity financing activity, executive appointments, and investor conference presentations.
Sana Biotechnology (NASDAQ:SANA) sold 21,607,878 common shares through its at-the-market (ATM) facility, generating net proceeds of about $69 million.
Including a previously announced $25 million Mayo Clinic investment, total capital raised since Q1 2026 is about $94 million, extending Sana's expected cash runway to mid-2027.
Sana Biotechnology (NASDAQ:SANA) reported Q1 2026 results and key pipeline updates. Cash and securities were $101.1 million with pro forma cash of $128.9 million, providing an expected runway into 2027. Net loss was $47.2 million (GAAP) and non-GAAP net loss was $38.8 million.
The company announced a strategic collaboration with Mayo Clinic on SC451, including a $25 million equity investment and an option for another $25 million. Updated 14‑month data from an investigator-sponsored trial of UP421 in type 1 diabetes showed ongoing beta cell survival, C‑peptide production, and no reported safety issues.
Sana continues preparations to start Phase 1 trials for SC451 and SG293 in 2026 and targets an SG227 multiple myeloma study as early as mid‑2027. Research and development expenses declined to $28.7 million, and non-GAAP operating cash burn was $37.0 million. Brian Piper was appointed Executive Vice President and Chief Financial Officer.
Sana Biotechnology (NASDAQ: SANA) will present at the BofA Securities 2026 Healthcare Conference on May 12, 2026 at 2:20 p.m. PT. Steve Harr, president and CEO, will give a business overview and company update. The presentation will be webcast on Sana's Investor Relations site and replayed for 30 days.
Sana Biotechnology (NASDAQ: SANA) announced an oral presentation of preclinical data for SG293, its CD19-directed in vivo CAR T candidate, accepted at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, May 11–15, 2026 in Boston.
The presentation, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293", is scheduled for May 12, 2026, 8:15–8:30 a.m. ET during the session on advancing in vivo gene delivery with non-AAV viral vector systems (Abstract No. 20; MCEC Room 257AB).
Sana Biotechnology (NASDAQ: SANA) and Mayo Clinic announced a strategic collaboration to accelerate development and delivery of SC451, Sana’s investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. Initial work will standardize handling, surgical technique, trial design, biomarkers, and post-treatment care.
As part of the agreement, Mayo Clinic will make an equity investment in Sana and has an option for an additional investment, supporting planned clinical trial start targeted for 2026.
Cell therapy manufacturing focus is shifting from clinical data to production capability. The market is projected to nearly double to >$14B by 2035, driven by automation and FDA flexible CMC oversight. Avaí Bio (OTCQB: AVAI) completed MCB preparations in February and began MCB production with Austrianova, supporting its α-Klotho program. Vericel received FDA approval to start commercial MACI manufacturing at Burlington in Q2 2026. Eledon (NASDAQ: ELDN) reported investigator-led islet transplant data with 10 patients >4 weeks post-transplant achieving insulin independence and mean HbA1c ~5.35%.
Sana Biotechnology (NASDAQ: SANA) reported 14-month follow-up from a first-in-human, investigator-sponsored study transplanting HIP-modified primary islet cells (UP421) into a patient with type 1 diabetes without immunosuppression.
The transplanted cells showed sustained survival and function, with fasting and MMTT-stimulated C-peptide present at month 14, comparable to the first six months; no safety issues were identified. Sana expects to file an IND for SC451 and initiate a Phase 1 trial as early as this year. Full 14-month data are being presented at ATTD on March 13, 2026.
Sana Biotechnology (NASDAQ: SANA) reported Q4 and full‑year 2025 results, highlighting clinical progress and financing. Key points: UP421 showed one‑year survival and function of hypoimmune islet cells without immunosuppression; NEJM published 12‑week results. Sana raised aggregate gross proceeds of $133.7M, held $138.4M cash at year‑end, and expects runway into late 2026. Company expects IND filing and Phase 1 start for SC451 and first‑in‑human data for SG293 as early as 2026. Reported R&D spend decline and a $44.6M impairment tied to facility strategy.
Sana Biotechnology (NASDAQ: SANA) will present live at two investor conferences in March 2026, with webcasts and 30-day replays available.
Sana will present a business overview and update at the Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:10 p.m. ET and at the Citizens Life Sciences Conference on March 11, 2026 at 1:40 p.m. ET. Webcasts are on the company Investor Relations page and replays remain for 30 days.
Sana Biotechnology (NASDAQ: SANA) appointed Brian Piper as Executive Vice President, Chief Financial Officer effective Feb. 17, 2026. Mr. Piper brings more than 25 years of biopharma finance and operations experience, including CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude, and Aevi.
The company expects initial clinical data in 12–18 months for SC451 (type 1 diabetes) and SG293 (B‑cell related disease); management says Piper will help manage capital formation, allocation, and operational execution as these programs advance.